What is the recommended evaluation and treatment for heavy menstrual bleeding (menorrhagia) in a woman?

Evaluation and Treatment for Heavy Menstrual Bleeding

For women with heavy menstrual bleeding, start with the levonorgestrel-releasing intrauterine system (LNG-IUS) as first-line treatment after ruling out pregnancy and underlying pathology, as it reduces menstrual blood loss by 71-95% and is comparable in efficacy to endometrial ablation.

Initial Evaluation

Clinical Assessment

• Rule out pregnancy first in all reproductive-age women 1
• Assess for hemodynamic instability: bleeding saturating a large pad or tampon hourly for ≥4 hours warrants urgent evaluation 1
• Check hemoglobin levels at least once to assess for anemia 2
• Obtain bleeding history focusing on:
  • Clots ≥1 inch diameter
  • "Flooding" (changing pad/tampon more than hourly)
  • Low ferritin levels
  • These predict significant blood loss 3

Screen for Underlying Causes

Consider an underlying gynecological problem including:

• Medications/drug interactions
• Sexually transmitted infections
• New pathologic uterine conditions (polyps, fibroids)
• Thyroid dysfunction
• Bleeding disorders (present in 10-62% of women with HMB, yet significantly underdiagnosed) 4

If personal or family history of bleeding exists, or if flooding/prolonged menses occur, refer to hematology 3.

Imaging

• Transvaginal ultrasound is the preferred initial imaging technique 2
• Use saline or gel infusion sonography if ultrasound suggests intracavitary abnormalities 2
• Perform hysteroscopy only if sonography results are inconclusive 2

When to Perform Endometrial Biopsy

Endometrial biopsy is indicated for:

• Women ≥35 years with recurrent anovulation
• Women <35 years with risk factors for endometrial cancer
• Excessive bleeding unresponsive to medical therapy 5

Important caveat: Endometrial biopsy is preferred over dilation and curettage (less invasive, safer, lower cost), but sensitivity can be affected by focal lesions 6.

Treatment Algorithm

First-Line Medical Treatment

Levonorgestrel-releasing intrauterine system (LNG-IUS 20 μg/day) 1, 2

• Reduces menstrual blood loss by 71-95%
• Efficacy comparable to endometrial ablation
• Main effect is at endometrial level with minimal systemic absorption
• Should be the very first treatment choice 2
• At 10-year follow-up, 43% of women continue using LNG-IUS alone or in combination 7

Alternative Medical Treatments (if LNG-IUS not suitable or desired)

For heavy or prolonged bleeding:

• NSAIDs for 5-7 days during bleeding 8, 9
  • Reduces blood loss by 20-60% 10
• Tranexamic acid for 5 days 9
  • Reduces blood loss by 20-60% 10
  • FDA-approved for ovulatory bleeding 5
  • Avoid in women with cardiovascular disease/SCAD due to thrombosis risk 1
• Combined oral contraceptives for 10-20 days (if medically eligible) 8
• Cyclic oral progestin reduces bleeding by 87% 1

Important distinction: Cyclic progestogens do NOT significantly reduce menstrual bleeding in women who ovulate 10.

When Medical Treatment Fails

If medical treatment fails or is unacceptable to the patient, proceed to:

1. Further investigation with imaging or hysteroscopy 6
2. Surgical options (in order of invasiveness):
   • Hysteroscopic resection (for submucosal fibroids) 2
   • Endometrial ablation (second-generation techniques preferred over first-generation) 2
     • Comparable efficacy to LNG-IUS 10
     • 29% of women undergo surgical intervention within 10 years 7
   • Uterine artery embolization (for uterine fibroids) 2
   • Hysterectomy (definitive treatment; 17% rate at 10-year follow-up) 5, 7

Special Populations

Women on Antiplatelet Therapy (post-SCAD)

• First step: Reassess indication for ongoing antiplatelet therapy and discontinue if appropriate 1
• Avoid NSAIDs and tranexamic acid (association with MI and thrombosis) 1
• Preferred treatment: LNG-IUS 20 μg/day 1
• Consider endometrial ablation techniques if medical management fails 1

Women with Bleeding Disorders

• Up to 20% of women with HMB have an inherited bleeding disorder 11
• Use hemostatic therapy: DDAVP or factor concentrates during menses 11
• Can combine with hormonal treatments 11

Common Pitfalls to Avoid

1. Don't delay pregnancy testing in reproductive-age women
2. Don't assume cyclic progestogens work for ovulatory bleeding - they don't 10
3. Don't miss bleeding disorders - use validated screening tools (PBAC, Philipp tool, self-BAT) 4
4. Don't use NSAIDs or tranexamic acid in women with cardiovascular disease 1
5. Don't perform hysteroscopy as first-line imaging - use transvaginal ultrasound first 2
6. Don't offer endometrial ablation as first-line - medical treatment should be tried first 6, 2